Peanut oral immunotherapy in very young children

Article Medicine, General & Internal

Efficacy and safety of oral immunotherapy in children aged 1–3 years with peanut allergy (the Immune Tolerance Network IMPACT trial): a randomised placebo-controlled study

Stacie M Jones et al.

LANCET (2022)

Article Allergy

First Real-World Effectiveness Analysis of Preschool Peanut Oral Immunotherapy

Lianne Soller et al.

Summary: Our data show that preschool peanut oral immunotherapy (P-OIT) is effective after 1 year of maintenance, with the majority of patients achieving a negative oral food challenge (OFC) result and a high proportion tolerating a cumulative dose of greater than or equal to 1000 mg. For those who experienced reactions, their threshold significantly increased, providing protection against accidental exposures. P-OIT may be considered as an alternative for preschoolers instead of avoidance strategies for peanut allergies.

JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY-IN PRACTICE (2021)

添加到收藏夹

Article Allergy

An Approach to the Office-Based Practice of Food Oral Immunotherapy

Richard L. Wasserman et al.

Summary: Oral immunotherapy (OIT) is an active treatment option for food allergy patients, improving quality of life and raising the threshold for allergen reactions. However, OIT requires a high level of commitment from clinicians, patients, and families, with recent guidelines and approvals accelerating its adoption.

JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY-IN PRACTICE (2021)

添加到收藏夹

Article Allergy